Larimar Therapeutics (LRMR) Long-Term Deferred Tax (2022 - 2023)
Larimar Therapeutics (LRMR) posted Long-Term Deferred Tax of $142.5 million for Q4 2023, up 237.74% on a QoQ basis from $42.2 million in Q4 2022, and up 237.74% year-over-year from $42.2 million in Q4 2022.
Larimar Therapeutics (LRMR) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Larimar Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $142.5 million for Q4 2023.
- Quarterly Long-Term Deferred Tax rose 237.74% year-over-year to $142.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $142.5 million (up 237.74% YoY) and the FY2023 annual result came in at $142.5 million, up 237.74% from the prior year.
- Long-Term Deferred Tax was $142.5 million for Q4 2023 at Larimar Therapeutics, up from $42.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $142.5 million in Q4 2023 and bottomed at $42.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 142.54 Mn |
| Dec 31, 2022 | 42.20 Mn |